Phaseline

Targets › MTAP

MTAP (S-methyl-5'-thioadenosine phosphorylase): drug programs, companies and trials

10 programs from 8 companies in 25 trials: 20 Phase 1, 5 Phase 2; Oncology, Other; next expected readout Nov 2026.

Catalyzes the phosphorolytic cleavage of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose1-phosphate. Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis. (UniProt, Q13126)

Open in Phaseline: the race on MTAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbNavlimetostat (BMS-986504)
Selective, MTA-cooperative PRMT5 inhibitor
PRMT5, MTAPPhase 2Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants …Nov 2026
Bristol-Myers SquibbBMS-986504 (MRTX1719)
Selective MTA-cooperative inhibitor of PRMT5
MTAP, PRMT5Phase 2Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion …Jan 2027
BeOne MedicinesBGB-58067
MTAP inhibitor
MTAPPhase 1Healthy Volunteers; Advanced Solid TumorJul 2027
Suzhou Genhouse Bio Co., Ltd.GH56 Capsule
MTAP inhibitor
MTAPPhase 1Advanced Solid Tumors With MTAP DeletionDec 2027
Heronova PharmaceuticalsDC50292A
MTAP inhibitor
MTAPPhase 1Solid Tumor MalignanciesJan 2028
Haisco Pharmaceutical GroupHSK41959
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorsMay 2028
Gilead SciencesGS-5319
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorMay 2028
Abbisko TherapeuticsABSK131
MTAP inhibitor
MTAPPhase 1Solid Tumors (Phase 1)Dec 2028
CytosinLab TherapeuticsCTS3497
MTAP inhibitor
MTAPPhase 1Solid TumorDec 2028
Gilead SciencesGS-2426
MTAP inhibitor
MTAPPhase 1Advanced Solid TumorsJan 2029

Conditions

Advanced Solid Tumors (3) Healthy Volunteers (2) Advanced Solid Tumor (2) Solid Tumors (1) Pancreatic Ductal Adenocarcinoma (1) Healthy Participants (1) Healthy Female Participants (1) Healthy Female Adults (1) Phase 2 Study (1) Non-Small Cell Lung Cancer (1) Advanced Cancer (1) Solid Tumor Malignancies (1)

Modalities

small molecule (9), mixed (1)

Companies

Bristol-Myers Squibb (2) Gilead Sciences (2) BeOne Medicines (1) Heronova Pharmaceuticals (1) Suzhou Genhouse Bio Co., Ltd. (1) CytosinLab Therapeutics (1) Haisco Pharmaceutical Group (1) Abbisko Therapeutics (1)

Related targets

PRMT5 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.